全文获取类型
收费全文 | 20428篇 |
免费 | 1278篇 |
国内免费 | 59篇 |
专业分类
耳鼻咽喉 | 331篇 |
儿科学 | 1104篇 |
妇产科学 | 501篇 |
基础医学 | 1773篇 |
口腔科学 | 354篇 |
临床医学 | 1598篇 |
内科学 | 4887篇 |
皮肤病学 | 327篇 |
神经病学 | 1034篇 |
特种医学 | 721篇 |
外科学 | 3725篇 |
综合类 | 458篇 |
一般理论 | 3篇 |
预防医学 | 1085篇 |
眼科学 | 899篇 |
药学 | 1546篇 |
1篇 | |
中国医学 | 71篇 |
肿瘤学 | 1347篇 |
出版年
2023年 | 145篇 |
2022年 | 321篇 |
2021年 | 760篇 |
2020年 | 404篇 |
2019年 | 606篇 |
2018年 | 704篇 |
2017年 | 489篇 |
2016年 | 496篇 |
2015年 | 503篇 |
2014年 | 787篇 |
2013年 | 989篇 |
2012年 | 1487篇 |
2011年 | 1347篇 |
2010年 | 847篇 |
2009年 | 663篇 |
2008年 | 997篇 |
2007年 | 1015篇 |
2006年 | 942篇 |
2005年 | 880篇 |
2004年 | 788篇 |
2003年 | 673篇 |
2002年 | 601篇 |
2001年 | 479篇 |
2000年 | 511篇 |
1999年 | 405篇 |
1998年 | 161篇 |
1997年 | 139篇 |
1996年 | 119篇 |
1995年 | 116篇 |
1994年 | 106篇 |
1993年 | 82篇 |
1992年 | 284篇 |
1991年 | 252篇 |
1990年 | 222篇 |
1989年 | 213篇 |
1988年 | 172篇 |
1987年 | 179篇 |
1986年 | 157篇 |
1985年 | 170篇 |
1984年 | 148篇 |
1983年 | 144篇 |
1982年 | 68篇 |
1981年 | 77篇 |
1979年 | 116篇 |
1978年 | 89篇 |
1977年 | 67篇 |
1974年 | 79篇 |
1973年 | 112篇 |
1972年 | 101篇 |
1971年 | 68篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
Rohi Shah Nomaan Sheikh Jitendra Mangwani Nicolette Morgan Hamidreza Khairandish 《Journal of Clinical Orthopaedics and Trauma》2021,12(1):138
Demographic projections for hip fragility fractures indicate a rising annual incidence by virtue of a multimorbid, ageing population with more noncommunicable diseases (NCDs). NCDs are characterised by slow progression and long duration ranging from ischaemic cardiovascular disease, cerebrovascular disease, diabetes, chronic obstructive pulmonary disease to various cancers. Management of this disease burden often involves commencing patients on oral anticoagulants to reduce the risk of thromboembolic events. The use of direct oral anticoagulants (DOACs) in clinical practice has increased due to their rapid onset of action, short half-life and predictable anticoagulant effects, without the need for routine monitoring. Safe and timely surgical intervention relies on reversal of anticoagulants. However, the lack of specific evidence-based guidelines for the perioperative management of patients on DOACs with hip fractures has proved challenging; in particular, the accessibility of DOAC-specific assays, justification of the cost-benefit ratio of targeted reversal agents and indications for neuraxial anaesthesia. This has led to potentially avoidable delays in surgical intervention. Following a literature review of the pharmacokinetic and pharmacodynamics of commonly used DOACs in our region including the role of surrogate markers, we propose a systematic, evidence-based guideline to the perioperative management of hip fractures DOACs. We believe this standardised protocol can be easily replicated between hospitals. We recommend that if patients are deemed suitable for a general anaesthesia, with satisfactory renal function, optimal surgical time should be 24 h following the last ingested dose of DOAC. 相似文献
4.
5.
6.
Marta López-Fauqued Laura Campora Frédérique Delannois Mohamed El Idrissi Lidia Oostvogels Ferdinandus J. De Looze Javier Diez-Domingo Thomas C. Heineman Himal Lal Janet E. McElhaney Shelly A. McNeil Wilfred Yeo Fernanda Tavares-Da-Silva 《Vaccine》2019,37(18):2482-2493
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献7.
Bryan Mclaughlin JungHwan Yang Woohyun Yoo Bret Shaw Soo Yun Kim Dhavan Shah 《Health communication》2016,31(6):762-771
The growth of online support groups has led to an expression effects paradigm within the health communication literature. Although religious support expression is characterized as a typical subdimension of emotional support, we argue that in the context of a life-threatening illness, the inclusion of a religious component creates a unique communication process. Using data from an online group for women with breast cancer, we test a theoretical expression effects model. Results demonstrate that for breast cancer patients, religious support expression has distinct effects from general emotional support messages, which highlights the need to further theorize expression effects along these lines. 相似文献
8.
9.
10.